# Mucuna Pruriens

> ''Mucuna pruriens — velvet bean, kapikacchu in Ayurveda — is the principal botanical source of L-DOPA''' (levodopa), the immediate metabolic precursor of dopamine and the mainstay drug of Parkinson's…

Canonical: https://wiki.soapbox.community/wiki/Mucuna_Pruriens
Section: Plants and preparation
Last updated: 2026-10-20
Publisher: Library of Ashurbanipal (Van Kush Family Research Institute), https://wiki.soapbox.community

***Mucuna pruriens*** — velvet bean, *kapikacchu* in Ayurveda — is the principal botanical source of **L-DOPA** (levodopa), the immediate metabolic precursor of dopamine and the mainstay drug of Parkinson's disease. Seed L-DOPA content is typically in the range of 3–7% by weight, which is high enough that the plant is not a mild herb in any useful sense: it is a dopaminergic drug that grows.

## Why the extraction method decides everything

L-DOPA is water-soluble and **degrades above 200 °C**. That single fact governs the whole preparation question:

- **Vaporisation is not a route.** At the temperatures that volatilise terpenes, L-DOPA is destroying rather than delivering. Where a cannabis-and-Mucuna combination is used, the Mucuna fraction is working **sublingually or orally** while the cannabis fraction is what is actually being vaporised. Those are two routes running at once, not one preparation.
- **Aqueous extraction** is the appropriate method for a VG/PG or tincture carrier — the compound follows the water.
- Heat during extraction is a loss term, not a solvent.

## Pharmacology

L-DOPA crosses the blood-brain barrier, where peripheral dopamine does not, and is decarboxylated to dopamine. In pharmaceutical use it is co-administered with a peripheral decarboxylase inhibitor (carbidopa or benserazide) precisely so that less of it is converted before it arrives. Whole-seed preparations carry no such inhibitor, so a much larger fraction is converted peripherally — which is where nausea, vomiting and blood-pressure effects come from.

Seed material also contains serotonin, nicotine, bufotenine and other minor alkaloids in small quantities; these are frequently cited in popular accounts and are not the reason the plant works.

## Cautions

This is the entry in the inventory that carries the most real risk, and it is worth being plain about it.

- **MAOIs.** L-DOPA with a monoamine oxidase inhibitor is a hypertensive-crisis interaction. This includes the harmala alkaloids in ayahuasca-type preparations and includes syrian rue. It is not a theoretical concern.
- **Existing dopaminergic therapy.** Anyone on levodopa, a dopamine agonist, or a COMT/MAO-B inhibitor is already dosing this axis; adding an uncalibrated botanical source stacks it.
- **Antipsychotics** act on the same system in the opposite direction.
- **Content varies.** L-DOPA percentage differs by cultivar, growing conditions and processing, so a gram of one powder is not a gram of another. Standardised extracts state a percentage; unstandardised seed powder does not.
- **Psychiatric history.** Dopaminergic load is relevant in psychosis and in impulse-control disorders, both of which are documented complications of dopaminergic therapy.
- **Blood pressure.** Both directions are reported.
- The **seed pod hairs** are a potent mechanical irritant — the source of the name "cowitch". This concerns raw plant handling, not prepared powder.

## In the inventory

Held as 1 lb of extract powder, designated for aqueous extraction rather than direct vaporiser use, for the reason given above.

See also: Stack Substances · Cannabinoid Oilahuasca · Imphepho